GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • Novartis digs into health tech with bet on "robotic pill" Wednesday, 27 May 2015 | 4:01 AM ET

    LONDON, May 27- Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection. Rani said it would run feasibility studies over the next 18-24 months to evaluate how selected Novartis biologic medicines can be...

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. The FDA has banned import of drugs from all of Ranbaxy's India- based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry,...

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • LONDON, May 7- GlaxoSmithKline's new chairman Philip Hampton has thrown his support behind the company's current structure and chief executive despite pressure from some shareholders for a change. Yet Hampton, also chairman of the Royal Bank of Scotland, said there is an issue about GSK's relative performance in terms of shareholder returns.

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • NEW YORK, May 7- New therapies that clinical data show can eliminate blood cancers such as leukemia and lymphoma in 40 percent to 90 percent of patients may have to be genetically modified to include a switch that shields healthy cells from attack. The therapies could generate tens of billions of dollars in annual sales for drugmakers including Kite Pharma and...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • GSK CEO: Why we're betting on drug volume, not price Wednesday, 6 May 2015 | 12:21 PM ET

    GlaxoSmithKline laid out growth targets for biggest businesses on Wednesday, hoping to convince investors that it would return to long-term growth.

  • It also scaled back plans to return 4 billion pounds of cash flowing from a $20 billion- plus asset swap with Novartis to investors, opting instead to pay a 1 billion special dividend. Chief Executive Andrew Witty is under pressure to demonstrate that the Novartis deal can revive GSK's fortunes by focusing it on consumer health and vaccines, following a slide in...

  • Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China. In a bid to protect its dividend, GSK scaled back plans to return 4 billion pounds of cash flowing from the Novartis transaction to...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • LONDON, May 6- GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's...

  • NEW YORK, May 1- U.S. authorities said on Friday that a unit of Express Scripts Holding Co will pay $60 million to resolve claims that it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. Specialty pharmacy Accredo Health Group Inc has agreed to pay $45.1 million to the federal government...

  • NEW YORK, May 1- A unit of pharmacy benefits manager Express Scripts Holding Co will pay $45 million to resolve U.S. claims it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. The settlement with specialty pharmacy Accredo Health Group Inc was disclosed in court papers filed Thursday in...

  • *Cash return was planned after Novartis asset swap deal. Instead, Britain's biggest drugmaker could use cash flowing in from its far-reaching asset swap deal with Novartis to support its dividend, according to analysts at Goldman Sachs and Berenberg Bank. GSK said last year it intended to return 4 billion pounds to shareholders in 2015 through a so-called B...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.